Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — Q2 2023 Earnings Presentation
21 slides from Nykode Therapeutics Asa's earnings presentation, Aug 23, 2023
Slide 1: Q2 2023 Results Presentation
Q2 2023 Results Presentation August 23, 2023
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Today's presenters from Nykode management
Today’s presenters from Nykode management International management team with solid drug development experience MICHAEL ENGSIG AGNETE FREDRIKSEN HARALD GURVIN Chief Executive Chief Business Officer & Chief Financial Officer Co-founder Officer Nykode Therapeutics | Q2 webcast | Non-confidential
Slide 4: Q2 2023 highlights
Q2 2023 highlights • Positive final results from Phase 2 trial of VB10.16 in advanced cervical cancer • Expansion of the clinical collaboration with Roche combining VB10.16 with atezolizumab in the potentially registrational trial, C-04, in advanced cervical cancer • Well-capitalized with a cash pos
Slide 5: Rich and diversified pipeline
Rich and diversified pipeline Upcoming Asset Indication Rights Preclinical Phase 1 Phase 2 Phase 3 Catalyst Oncology Initiate trial HPV16+ cervical cancer 1 (Q4 2023) VB10.16 FPFD HPV16+ head and neck cancer 2 (Q3 2023) Off-the-shelf Regeneron programs Undisclosed 3 Update Internal Undisclosed (Q4 2
Slide 6: R&D update
R&D update Nykode Therapeutics | Q2 webcast | Non-confidential
Slide 7: VB10.16: Therapeutic vaccine candidate for HPV16+ cancers
VB10.16: Therapeutic vaccine candidate for HPV16+ cancers Targeting unit Off-the-shelf therapeutic cancer DNA vaccine CCL3L1 against HPV16 induced malignancies HPV16 is the most prevalent oncogenic HPV strain VB10.16 Targeting the cancer-specific full-length HPV16 E7 and E6 Off-the-shelf vaccine
Slide 8: VB10.16 highlights: Targeted vaccines for HPV16+ cancers
VB10.16 highlights Targeted vaccines for HPV16+ cancers C-02 C-03 C-04 Unresectable recurrent or Indication Advanced Cervical Cancer metastatic head and neck Cervical Cancer cancer (HNSCC) and PD-L1+ 3 mg in combination with Up to 9 mg in combination with In combination with Dose atezolizumab (Tecen
Slide 9: Data from the VB10.16 Ph2 trial compared with current and future SoC
Data from the VB10.16 Ph2 trial compared with relevant current and future SoC as evaluated in third-party trials Cemiplimab in PD-L1+ Tisotumab vedotin VB10.16 plus atezolizumab Pembrolizumab in PD-L1+ Endpoint (Empower-Cervical 1, (PD-L1 agnostic) in PD-L1+ (n = 24) (Keynote-158, n = 82)** n = 82,
Slide 10: C-02 data supports patient population selection for future trials
C-02 data supports patient population selection for future trials Clinical activity observed across all endpoints in PD-L1+ patients Strongest results in PD-L1+ patients with 1 prior line of systemic therapy, support potential in patient populations selected for future trials Endpoint PD-L1+ PD-
Slide 11: VB10.NEO: leading technology for individualized cancer neoantigen immunotherapy
VB10.NEO: leading technology for individualized cancer neoantigen immunotherapy Strong in-house bioinformatic competences and proprietary neoantigen selection method Trained on Nykode’s data and unique broad CD8 dominated immune response Focus on clonal and clinically relevant epitopes High qu
Slide 12: VB10.NEO highlights
VB10.NEO highlights Safety clearance of 9 mg dose with no safety concerns and no dose limiting toxicities observed N-01 N-02 Melanoma, non-small cell lung cancer (NSCLC), clear Locally advanced and Indication renal cell carcinoma, urothelial cancer or squamous metastatic tumors covering cell carcino
Slide 13: Other R&D highlights
Other R&D highlights Oncology: Progressing internal programs to select new development candidate in Q4 2023. Autoimmune disorders: Established dedicated Autoimmune research group, effective Henrik Søndergaard from September 1, 2023. Head of Tolerance Appointment of Henrik Søndergaard as Head of Tole
Slide 14: Q2 2023 Financial Results
Q2 2023 Financial Results
Slide 15: Strong financial foundation for achieving our vision
Strong financial foundation for achieving our vision Cash position of $174m end Q2 2023 Financially well positioned to execute the Company’s strategy over the next years Nykode continues to explore a potential listing on the Nasdaq Global Market in the United States Nykode Therapeutics | Q2 webc
Slide 16: Income Statement
Income Statement Revenue from contracts with customers Amounts in USD ‘000 Q2 2023 Q2 2022 YTD 2023 YTD 2022 • R&D activities under Genentech and Regeneron Revenue from contracts with customers 5,000 3,114 8,126 3,830 agreements Other income 100 309 281 617 • $4.9m (Q2 2023) and $7.4m (1H 2023) unde
Slide 17: Balance Sheet
Balance Sheet Cash and cash equivalents Amounts in USD ‘000 30/06/2023 31/12/2022 • Strong cash position of $174m at June 30, 2023 ASSETS Non-current assets Property, plant and equipment 3,981 3,517 Trade receivables Right-of-use assets 6,920 6,009 • Reduction due to receipt of $2.5m milestone under
Slide 18: Balance Sheet - contd.
Balance Sheet - contd. Amounts in USD ’000 30/06/2023 31/12/2022 Equity EQUITY AND LIABILITIES • Total equity of $140m as per June 30, 2023 Equity Share capital 339 338 • Equity ratio of 74% Share premium 84,145 83,318 Other capital reserves 13,115 11,694 Other components of equity (3,037) (3,044) C
Slide 19: Rich calendar of milestones expected in the next months
Rich calendar of milestones expected in the next 12 months VB10.16 ✓ 1H 2023 Final results from VB-C-02 Phase 2 study; 12 month treatment follow-up Cervical Cancer 2H VB10.16 First patient dosed in C-03 trial with KEYTRUDA®1 in patients with PD-L1 positive 2023 1st line unresectable recurrent or met
Slide 20: Save the date: Capital Markets Days
SAVE THE DATE! Nykode to a host a Capital Markets Days in NYC and Oslo. Members of the Management Team and a Key Opinion Leader will present latest updates on the Vaccibody platform and its clinical programs: • NYC - September 20, 2023 • Oslo - September 27, 2023 Stay tuned! Nykode Nykode Therapeuti
Slide 21: Unlocking the future of medicine
UNLOCKING THE FUTURE OF MEDICINE Contact: Agnete Fredriksen CBO & Co-founder IR@nykode.com Nykode Therapeutics | Q2 webcast | Non-confidential